These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15180599)

  • 1. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.
    Barrass BJ; Thurairaja R; Persad RA
    BJU Int; 2004 Jun; 93(9):1175-6. PubMed ID: 15180599
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
    Izumi K; Mizokami A; Namiki M
    Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 4. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteoporosis prophylaxis in men? Adverse effects of total androgen blockade in carcinoma of the prostate].
    Hüfner M
    Internist (Berl); 1999 Aug; 40(8):883. PubMed ID: 10476490
    [No Abstract]   [Full Text] [Related]  

  • 6. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Osteoporosis due to androgen suppression therapy in men with prostate cancer].
    Roux C
    Prog Urol; 2003 Apr; 13(2 Suppl 1):24-7. PubMed ID: 12815806
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM; Pasini J; Mareković Z
    Coll Antropol; 2005 Dec; 29(2):589-91. PubMed ID: 16417166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer treated with androgen deprivation therapy has consequences for bone.
    Adler RA
    Endocrine; 2014 Apr; 45(3):339-40. PubMed ID: 24366636
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
    Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
    Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
    Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
    Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS; Ryan CW; Jung LL
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of fracture after androgen deprivation for prostate cancer.
    Walsh PC
    J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.